SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

2seventy bio, Inc. – ‘10-K’ for 12/31/23 – ‘EX-97.1’

On:  Thursday, 3/7/24, at 4:02pm ET   ·   For:  12/31/23   ·   Accession #:  1860782-24-27   ·   File #:  1-40791

Previous ‘10-K’:  ‘10-K/A’ on 12/1/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   10 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/07/24  2seventy bio, Inc.                10-K       12/31/23  121:13M

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.76M 
 2: EX-10.14    Material Contract                                   HTML     48K 
 3: EX-19.1     Report Furnished to Security Holders                HTML     82K 
 4: EX-23.1     Consent of Expert or Counsel                        HTML     34K 
 8: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     53K 
                Awarded Compensation                                             
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     37K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     37K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     36K 
14: R1          Cover                                               HTML    104K 
15: R2          Audit Information                                   HTML     39K 
16: R3          Consolidated Balance Sheets                         HTML    140K 
17: R4          Consolidated Balance Sheets (Parenthetical)         HTML     54K 
18: R5          Consolidated and Combined Statements of Operations  HTML    132K 
                and Comprehensive Loss                                           
19: R6          Consolidated and Combined Statements of Operations  HTML     38K 
                and Comprehensive Loss (Parenthetical)                           
20: R7          Consolidated and Combined Statements of             HTML    116K 
                Stockholders' Equity                                             
21: R8          Consolidated and Combined Statements of             HTML     36K 
                Stockholders' Equity (Parenthetical)                             
22: R9          Consolidated and Combined Statements of Cash Flows  HTML    136K 
23: R10         Description of the business                         HTML     46K 
24: R11         Summary of significant accounting policies and      HTML    207K 
                basis of presentation                                            
25: R12         Marketable securities                               HTML    127K 
26: R13         Fair value measurements                             HTML     94K 
27: R14         Property, plant and equipment, net                  HTML     48K 
28: R15         Accrued expenses and other current liabilities      HTML     47K 
29: R16         Leases                                              HTML     65K 
30: R17         Commitments and contingencies                       HTML     52K 
31: R18         Stockholders' equity                                HTML     54K 
32: R19         Collaborative arrangements and strategic            HTML    214K 
                partnerships                                                     
33: R20         Royalty and other revenue                           HTML     38K 
34: R21         Intangible assets                                   HTML     59K 
35: R22         Stock-based compensation                            HTML     93K 
36: R23         Related-party transactions                          HTML     62K 
37: R24         401(k) Savings plan                                 HTML     39K 
38: R25         Income taxes                                        HTML    101K 
39: R26         Net loss per share                                  HTML     44K 
40: R27         Corporate restructuring                             HTML     43K 
41: R28         Goodwill impairment                                 HTML     45K 
42: R29         Subsequent events                                   HTML     43K 
43: R30         Pay vs Performance Disclosure                       HTML     46K 
44: R31         Insider Trading Arrangements                        HTML     40K 
45: R32         Summary of significant accounting policies and      HTML    220K 
                basis of presentation (Policies)                                 
46: R33         Summary of significant accounting policies and      HTML    234K 
                basis of presentation (Tables)                                   
47: R34         Marketable securities (Tables)                      HTML    130K 
48: R35         Fair value measurements (Tables)                    HTML    125K 
49: R36         Property, plant and equipment, net (Tables)         HTML     46K 
50: R37         Accrued expenses and other current liabilities      HTML     45K 
                (Tables)                                                         
51: R38         Leases (Tables)                                     HTML     58K 
52: R39         Commitments and contingencies (Tables)              HTML     39K 
53: R40         Stockholders' equity (Tables)                       HTML     43K 
54: R41         Collaborative arrangements and strategic            HTML    173K 
                partnerships (Tables)                                            
55: R42         Intangible assets (Tables)                          HTML     59K 
56: R43         Stock-based compensation (Tables)                   HTML     91K 
57: R44         Related-party transactions (Tables)                 HTML     41K 
58: R45         Income taxes (Tables)                               HTML     97K 
59: R46         Net loss per share (Tables)                         HTML     44K 
60: R47         Corporate restructuring (Tables)                    HTML     41K 
61: R48         Goodwill impairment (Tables)                        HTML     43K 
62: R49         Description of the business - Narrative (Detail)    HTML     62K 
63: R50         Summary of significant accounting policies and      HTML     69K 
                basis of presentation - Narrative (Detail)                       
64: R51         Summary of significant accounting policies and      HTML     79K 
                basis of presentation - Correction of Immaterial                 
                Error (Details)                                                  
65: R52         Summary of significant accounting policies and      HTML     47K 
                basis of presentation - Estimated Useful Lives of                
                Assets (Detail)                                                  
66: R53         Summary of significant accounting policies and      HTML     55K 
                basis of presentation - Service Revenue (Details)                
67: R54         Summary of significant accounting policies and      HTML     43K 
                basis of presentation - Collaborative Arrangement                
                Revenue (Details)                                                
68: R55         Marketable securities - Summary of Marketable       HTML     52K 
                Securities (Details)                                             
69: R56         Marketable securities - Schedule of Unrealized      HTML     65K 
                Loss on Investments (Details)                                    
70: R57         Marketable securities - Summary of Restricted       HTML     48K 
                Investments (Details)                                            
71: R58         Marketable securities - Schedule of Unrealized      HTML     51K 
                Loss on Restricted Investments (Details)                         
72: R59         Marketable securities - Narrative (Details)         HTML     39K 
73: R60         Fair value measurements - Recorded Amount of        HTML     88K 
                Assets and Liabilities Measured at Fair Value on                 
                Recurring Basis (Detail)                                         
74: R61         Fair value measurements - Roll-Forward of Fair      HTML     46K 
                Value of the Company's Contingent Consideration                  
                Obligations (Detail)                                             
75: R62         Property, plant and equipment, net - Summary of     HTML     53K 
                Property, Plant and Equipment, Net (Detail)                      
76: R63         Property, plant and equipment, net - Narrative      HTML     43K 
                (Detail)                                                         
77: R64         Accrued expenses and other current liabilities -    HTML     49K 
                Summary of Accrued Expenses and Other Current                    
                Liabilities (Detail)                                             
78: R65         Accrued expenses and other current liabilities -    HTML     37K 
                Narrative (Details)                                              
79: R66         Leases - Narrative (Details)                        HTML     85K 
80: R67         Leases - Summary of Lease Costs and Other           HTML     50K 
                Information Pertaining to Operating Leases                       
                (Details)                                                        
81: R68         Leases - Schedule of Future Minimum Commitments     HTML     50K 
                Under Operating Leases (Details)                                 
82: R69         Commitments and contingencies - Narrative (Detail)  HTML     45K 
83: R70         Commitments and contingencies - Schedule of         HTML     39K 
                Non-cancelable Contractual Obligations (Detail)                  
84: R71         Stockholders' equity - Narrative (Details)          HTML    105K 
85: R72         Stockholders' equity - Common Stock Reserved for    HTML     46K 
                Future Issuance (Details)                                        
86: R73         Collaborative arrangements and strategic            HTML    304K 
                partnerships - Narrative (Detail)                                
87: R74         Collaborative arrangements and strategic            HTML     47K 
                partnerships - Summary of Total Transaction Price,               
                Allocation of Total Transaction Price to                         
                Identified Performance Obligations Under                         
                Arrangement and Amount of Transaction Price                      
                Unsatisfied (Detail)                                             
88: R75         Collaborative arrangements and strategic            HTML     63K 
                partnerships - Summary of Revenue Recognized or                  
                Expense Incurred for Joint Ide-cel Development                   
                Efforts Related to Combined Unit of Accounting for               
                its License and Vector Manufacturing of Ide-cel                  
                (Detail)                                                         
89: R76         Collaborative arrangements and strategic            HTML     51K 
                partnerships - Collaborative Arrangement Revenue                 
                (Detail)                                                         
90: R77         Collaborative arrangements and strategic            HTML     50K 
                partnerships - Summary of Amounts Associated with                
                Research and Development Services (Detail)                       
91: R78         Collaborative arrangements and strategic            HTML     48K 
                partnerships - Changes in Balances of Company's                  
                Receivables and Contract Liabilities (Detail)                    
92: R79         Collaborative arrangements and strategic            HTML     50K 
                partnerships - Summary of Transaction Price                      
                Allocation (Details)                                             
93: R80         Royalty and other revenue - Narrative (Detail)      HTML     43K 
94: R81         Intangible assets - Schedule of Finite-Lived        HTML     46K 
                Intangible Assets (Details)                                      
95: R82         Intangible assets - Narrative (Detail)              HTML     40K 
96: R83         Intangible assets - Schedule of Finite-Lived        HTML     49K 
                Intangible Assets, Future Amortization Expense                   
                (Details)                                                        
97: R84         Stock-based compensation - Narrative (Detail)       HTML     88K 
98: R85         Stock-based compensation - Schedule of Stock-Based  HTML     49K 
                Compensation Expense by Classification (Detail)                  
99: R86         Stock-based compensation - Summary of Stock-Based   HTML     51K 
                Compensation Expense by Award Type (Detail)                      
100: R87         Stock-based compensation - Assumptions Used for     HTML     43K  
                the Black-Scholes Option-Pricing Model to                        
                Determine the Per Share Weighted Average Fair                    
                Value for Options Granted (Detail)                               
101: R88         Stock-based compensation - Summary of Stock Option  HTML     86K  
                Activity Under Plan (Detail)                                     
102: R89         Stock-based compensation - Summary of Restricted    HTML     58K  
                Stock Units (Detail)                                             
103: R90         Related-party transactions - Narrative (Details)    HTML     76K  
104: R91         Related-party transactions - Imputed Charges        HTML     51K  
                (Details)                                                        
105: R92         401(k) Savings plan - Narrative (Detail)            HTML     35K  
106: R93         Income taxes - Schedule of Components of Loss       HTML     51K  
                Before Income Taxes (Detail)                                     
107: R94         Income taxes - Reconciliation of Income Tax         HTML     64K  
                Provision (Benefit) (Detail)                                     
108: R95         Income taxes - Components of Deferred Tax Assets    HTML     61K  
                and Liabilities (Detail)                                         
109: R96         Income taxes - Narrative (Detail)                   HTML     54K  
110: R97         Income taxes - Reconciliation of Unrecognized Tax   HTML     41K  
                Benefits (Detail)                                                
111: R98         Net loss per share - Common Stock Equivalents       HTML     45K  
                Excluded from the Calculation of Diluted Net Loss                
                per Share (Details)                                              
112: R99         Corporate restructuring - Narrative (Details)       HTML     43K  
113: R100        Corporate restructuring - Summary of Accrued        HTML     44K  
                Liability Activity (Details)                                     
114: R101        Goodwill impairment - Narrative (Details)           HTML     45K  
115: R102        Goodwill impairment - Summary of Goodwill Activity  HTML     43K  
                (Details)                                                        
116: R103        Subsequent events (Details)                         HTML     50K  
118: XML         IDEA XML File -- Filing Summary                      XML    225K  
121: XML         XBRL Instance -- tsvt-20231231_htm                   XML   2.94M  
117: EXCEL       IDEA Workbook of Financial Report Info              XLSX    266K  
10: EX-101.CAL  XBRL Calculations -- tsvt-20231231_cal               XML    245K 
11: EX-101.DEF  XBRL Definitions -- tsvt-20231231_def                XML   1.10M 
12: EX-101.LAB  XBRL Labels -- tsvt-20231231_lab                     XML   2.35M 
13: EX-101.PRE  XBRL Presentations -- tsvt-20231231_pre              XML   1.69M 
 9: EX-101.SCH  XBRL Schema -- tsvt-20231231                         XSD    302K 
119: JSON        XBRL Instance as JSON Data -- MetaLinks              670±  1.03M  
120: ZIP         XBRL Zipped Folder -- 0001860782-24-000027-xbrl      Zip    745K  


‘EX-97.1’   —   Clawback Policy re: Recovery of Erroneously Awarded Compensation


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  Document  

2SEVENTY BIO, INC.
COMPENSATION RECOVERY POLICY
Adopted as of September 26, 2023
2seventy bio, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. This Policy supersedes and replaces the Company’s Policy for Recoupment of Incentive Compensation, dated as of September __, 2021 (the “Prior Policy”) with respect to Incentive Compensation received after the Effective Date (as defined below).
1.    Overview
The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons in accordance with rules issued by the United States Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Nasdaq Stock Market. Capitalized terms used and not otherwise defined herein shall have the meanings given in Section 3 below.
2.    Compensation Recovery Requirement
In the event the Company is required to prepare a Financial Restatement, the Company shall recover reasonably promptly all Erroneously Awarded Compensation with respect to such Financial Restatement.
3.    Definitions
a.Applicable Recovery Period” means the three completed fiscal years immediately preceding the Restatement Date for a Financial Restatement. In addition, in the event the Company has changed its fiscal year: (i) any transition period of less than nine months occurring within or immediately following such three completed fiscal years shall also be part of such Applicable Recovery Period and (ii) any transition period of nine to 12 months will be deemed to be a completed fiscal year.
b.Applicable Rules” means any rules or regulations adopted by the Exchange pursuant to Rule 10D-1 under the Exchange Act and any applicable rules or regulations adopted by the SEC pursuant to Section 10D of the Exchange Act.
c.Board” means the Board of Directors of the Company.
d.Committee” means the Compensation Committee of the Board or, in the absence of such committee, a majority of independent directors serving on the Board.
e.Covered Person” means any Executive Officer and any other person designated by the Board or the Committee as being subject to this Policy, as listed in Schedule A attached hereto, which schedule may be updated from time to time by the Committee. A person’s status as a Covered Person with respect to Erroneously Awarded Compensation shall be determined as of the time of receipt of such Erroneously Awarded Compensation regardless of the person’s current role or status with the Company (e.g., if a person began service as an Executive Officer after the beginning of an Applicable Recovery Period, that person would not be considered a Covered



Person with respect to Erroneously Awarded Compensation received before the person began service as an Executive Officer, but would be considered a Covered Person with respect to Erroneously Awarded Compensation received after the person began service as an Executive Officer where such person served as an Executive Officer at any time during the performance period for such Erroneously Awarded Compensation).
f.Effective Date” means September 26, 2023.
g.Erroneously Awarded Compensation” means the amount of any Incentive-Based Compensation received by a Covered Person on or after the Effective Date and during the Applicable Recovery Period that exceeds the amount that otherwise would have been received by the Covered Person had such compensation been determined based on the restated amounts in a Financial Restatement, computed without regard to any taxes paid. Calculation of Erroneously Awarded Compensation with respect to Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Financial Restatement, shall be based on a reasonable estimate of the effect of the Financial Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company shall maintain documentation of the determination of such reasonable estimate and provide such documentation to the Exchange in accordance with the Applicable Rules. Incentive-Based Compensation is deemed received, earned, or vested when the Financial Reporting Measure is attained, not when the actual payment, grant, or vesting occurs.
h.Exchange” means the Nasdaq Stock Market LLC.
i.Executive Officer” means any person who served the Company in any of the following roles at any time during the performance period applicable to Incentive-Based Compensation such person received during service in such role: the president, principal financial officer, principal accounting officer (or if there is no such accounting officer the controller), any vice president in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy making function, or any other person who performs similar policy making functions for the Company. Executive officers of parents or subsidiaries of the Company may be deemed executive officers of the Company if they perform such policy making functions for the Company.
j.Financial Reporting Measures” mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, any measures that are derived wholly or in part from such measures (including, for example, a non-GAAP financial measure), and stock price and total shareholder return.
k.Incentive-Based Compensation” means any compensation provided, directly or indirectly, by the Company or any of its subsidiaries that is granted, earned, or vested based, in whole or in part, upon the attainment of a Financial Reporting Measure and any equity-based compensation provided by the Company or any of its subsidiaries, including, without limitation, stock options, restricted stock awards, restricted stock units, and stock appreciation rights, regardless of whether such equity-based compensation is granted, earned, or vested based, in whole or in part, upon the attainment of a Financial Reporting Measure.
2


l.Financial Restatement” means a restatement of previously issued financial statements of the Company due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required restatement to correct an error in previously-issued financial statements that is material to the previously-issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
m.Restatement Date” means, with respect to a Financial Restatement, the earlier to occur of: (i) the date the Board, a committee of the Board or the officer or officers of the Company authorized to take such action if Board action is not required concludes, or reasonably should have concluded, that the Company is required to prepare the Financial Restatement or (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare the Financial Restatement.
4.    Exception to Compensation Recovery Requirement
The Company may elect not to recover Erroneously Awarded Compensation pursuant to this Policy if the Committee determines that recovery would be impracticable, and one or more of the following conditions, together with any further requirements set forth in the Applicable Rules, are met: (i) the direct expense paid to a third party, including outside legal counsel, to assist in enforcing this Policy would exceed the amount to be recovered, and the Company has made a reasonable attempt to recover such Erroneously Awarded Compensation; or (ii) recovery would likely cause an otherwise tax-qualified retirement plan to fail to be so qualified under applicable regulations.
5.     Recovery from Participating Employees.
In addition to (and without limiting) the provisions of paragraph 2 above, in the event the Company is required to prepare a Financial Restatement after the Effective Date, the Company may recover from any current or former employee of the Company who is not a Covered Person (each a “Participating Employee”) and who received Incentive-Based Compensation from the Company during the three completed fiscal years immediately preceding the date on which the Board, a committee of the Board or the officer or officers of the Company authorized to take such action if Board action is not required concludes that the Company is required to prepare a Financial Restatement, the amount that exceeds what would have been paid to the Participating Employee under the Financial Restatement; provided that, this paragraph 5 will apply only to the extent the Board (or a duly established committee thereof), in its sole discretion, determines that the Participating Employee committed any act or omission that materially contributed to the circumstances requiring the Financial Restatement and such act or omission involved any of the following: (i) misconduct, wrongdoing or a violation of any of the Company’s rules or of any applicable legal or regulatory requirements in the course of the Participating Employee’s employment by the Company; or (ii) a breach of a fiduciary duty to the Company or its stockholders by the Participating Employee.
6.     Recovery Where Intentional Misconduct.
In addition to (and without limiting) the provisions of paragraphs 2 and 5 above, in the event the Company is required to prepare a Financial Restatement after the Effective Date and the Board (or a duly established committee thereof), in its sole discretion, determines that a Covered Person’s or a Participating Employee’s act or omission contributed to the circumstances requiring the Financial Restatement and such act or omission involved any of the following: (i) willful, knowing or intentional misconduct or a willful, knowing or intentional violation of any of the Company’s rules or any applicable legal or regulatory requirements in the course of the
3


Covered Person’s or the Participating Employee’s employment by the Company or (ii) fraud in the course of the Covered Person’s or the Participating Employee’s employment by the Company, the Company may recover from such Covered Person or Participating Employee up to 100% (as determined by the Board or a duly established committee thereof in its sole discretion) of the Incentive-Based Compensation received by such Covered Person or Participating Employee from the Company during the three fiscal years preceding the date on which the Company determined that it is required to prepare a Financial Restatement.
7.    Tax Considerations
To the extent that, pursuant to this Policy, the Company is entitled to recover any Erroneously Awarded Compensation that is received by a Covered Person, the gross amount received (i.e., the amount the Covered Person received, or was entitled to receive, before any deductions for tax withholding or other payments) shall be returned by the Covered Person.
8.    Method of Compensation Recovery
The Committee shall determine, in its sole discretion, the method for recovering Erroneously Awarded Compensation hereunder, which may include, without limitation, any one or more of the following:
a.requiring reimbursement of cash Incentive-Based Compensation previously paid;
b.seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;
c.cancelling or rescinding some or all outstanding vested or unvested equity-based awards;
d.adjusting or withholding from unpaid compensation or other offset;
e.cancelling or offsetting against planned future grants of equity-based awards; and/or
f.any other method permitted by applicable law or contract.
Notwithstanding the foregoing, a Covered Person will be deemed to have satisfied such person’s obligation to return Erroneously Awarded Compensation to the Company if such Erroneously Awarded Compensation is returned in the exact same form in which it was received; provided that equity withheld to satisfy tax obligations will be deemed to have been received in cash in an amount equal to the tax withholding payment made.
9.     Policy Interpretation
This Policy shall be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law. The Committee shall take into consideration any applicable interpretations and guidance of the SEC in interpreting this Policy, including, for example, in determining whether a financial restatement qualifies as a Financial Restatement hereunder. To the extent the Applicable Rules require recovery of Incentive-Based Compensation in additional circumstances besides those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive-Based Compensation to the fullest extent required by the Applicable Rules.
10.    Policy Administration
4


This Policy shall be administered by the Committee. The Committee shall have such powers and authorities related to the administration of this Policy as are consistent with the governing documents of the Company and applicable law. The Committee shall have full power and authority to take, or direct the taking of, all actions and to make all determinations required or provided for under this Policy and shall have full power and authority to take, or direct the taking of, all such other actions and make all such other determinations not inconsistent with the specific terms and provisions of this Policy that the Committee deems to be necessary or appropriate to the administration of this Policy. The interpretation and construction by the Committee of any provision of this Policy and all determinations made by the Committee under this policy shall be final, binding, and conclusive.
11.    Compensation Recovery Repayments Not Subject to Indemnification
Notwithstanding anything to the contrary set forth in any agreement with, or the organizational documents of, the Company or any of its subsidiaries, Covered Persons are not entitled to indemnification for Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered under this Policy.

5



Schedule A

Nick Leschly, Chief Executive Officer
William Baird, Chief Operating Officer
Steven Bernstein, Chief Medical Officer
Philip Gregory, Chief Scientific Officer
Susan Abu-Absi, Chief Technology Officer
Teresa Jurgensen, General Counsel
Kathy Wilkinson, Chief People Officer
Kerri Jensen, VP, Talent & Experience
Jenn Snyder, SVP Corporate Communications


6

Dates Referenced Herein

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/7/24None on these Dates
For Period end:12/31/23
9/26/23
 List all Filings 


10 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/30/24  2seventy bio, Inc.                8-K:1,2,5,7 1/28/24   14:507K
 8/14/23  2seventy bio, Inc.                10-Q        6/30/23   75:7.1M
 5/10/23  2seventy bio, Inc.                10-Q        3/31/23   73:6.8M
 5/12/22  2seventy bio, Inc.                10-Q        3/31/22   70:5.7M
 3/22/22  2seventy bio, Inc.                10-K       12/31/21  104:15M
 3/16/22  2seventy bio, Inc.                8-K:1,2,3,7 3/15/22   13:684K                                   Workiva Inc Wde… FA01/FA
11/04/21  2seventy bio, Inc.                8-K:1,2,3,511/01/21   24:6.2M                                   Workiva Inc Wde… FA01/FA
10/08/21  2seventy bio, Inc.                10-12B/A              21:10M                                    Workiva Inc Wde… FA01/FA
 9/09/21  2seventy bio, Inc.                10-12B                11:6.6M                                   Workiva Inc Wde… FA01/FA
 5/04/16  bluebird bio, Inc.                10-Q        3/31/16   60:6.5M                                   ActiveDisclosure/FA
Top
Filing Submission 0001860782-24-000027   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 6:30:26.2pm ET